Calidi Biotherapeutics Inc. (CLDI) disclosed that its 2025 financial statements include an auditor's warning about its ability to continue as a going concern, sending shares down 8.39 percent.
"Release of this information is required by Section 610(b) of the NYSE American Company Guide and does not reflect any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025," the company said in a press release.
The stock-specific pressure pushed shares to $0.1758, far below the 200-day moving average of $1.20 and a 52-week high of $19.20. The move came on a relative volume of 0.16x the 20-day average, while biotech peers like APRE and CELZ saw gains. The company's Q1 2026 report showed a cash balance of $6.8 million.
The auditor's note raises questions about Calidi's financial stability as it works to fund its pipeline of cancer therapies. The company is advancing its lead candidate, CLD-401, toward an Investigational New Drug (IND) submission planned by the end of 2026.
The "going concern" explanatory paragraph in an audit report signals that the accounting firm has substantial doubt about a company's ability to meet its financial obligations over the next year. While Calidi emphasized the disclosure is a regulatory formality required by the exchange, it officially puts investors on notice about the company's financial runway.
The company is pioneering its RedTail platform, which uses an engineered virus to deliver genetic medicines to tumor sites. It has recently presented positive data for its CLD-401 asset and T-cell engager programs at scientific conferences. However, the forward-looking statements in its own press release acknowledge the "risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials."
The market's reaction reflects concerns about future financing. While the disclosure created selling pressure, recent institutional filings from Q1 2026 show some firms taking new positions. Armistice Capital LLC added 879,000 shares, and Sabby Management LLC added 434,903 shares. In contrast, insider activity in the last six months shows one sale by director Allan Camaisa, who sold 850 shares.
The disclosure crystallizes the primary risk for the pre-revenue biotech company. For Calidi, the path forward depends on its ability to secure new funding to continue its research and development. Investors will be closely watching for progress on its planned IND submission for CLD-401 by the end of 2026 as the next major catalyst.
This article is for informational purposes only and does not constitute investment advice.
